Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients. / Wesołowska-Andersen, A; Borst, L; Dalgaard, M D; Yadav, R; Rasmussen, K K; Wehner, P S; Rasmussen, Morten; Ørntoft, T F; Nordentoft, I; Koehler, R; Bartram, C R; Schrappe, M; Sicheritz-Ponten, T; Gautier, L; Marquart, H; Madsen, H O; Brunak, S; Stanulla, M; Gupta, R; Schmiegelow, K.

I: Leukemia, Bind 29, Nr. 2, 2015, s. 297-303.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Wesołowska-Andersen, A, Borst, L, Dalgaard, MD, Yadav, R, Rasmussen, KK, Wehner, PS, Rasmussen, M, Ørntoft, TF, Nordentoft, I, Koehler, R, Bartram, CR, Schrappe, M, Sicheritz-Ponten, T, Gautier, L, Marquart, H, Madsen, HO, Brunak, S, Stanulla, M, Gupta, R & Schmiegelow, K 2015, 'Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients', Leukemia, bind 29, nr. 2, s. 297-303. https://doi.org/10.1038/leu.2014.205

APA

Wesołowska-Andersen, A., Borst, L., Dalgaard, M. D., Yadav, R., Rasmussen, K. K., Wehner, P. S., Rasmussen, M., Ørntoft, T. F., Nordentoft, I., Koehler, R., Bartram, C. R., Schrappe, M., Sicheritz-Ponten, T., Gautier, L., Marquart, H., Madsen, H. O., Brunak, S., Stanulla, M., Gupta, R., & Schmiegelow, K. (2015). Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients. Leukemia, 29(2), 297-303. https://doi.org/10.1038/leu.2014.205

Vancouver

Wesołowska-Andersen A, Borst L, Dalgaard MD, Yadav R, Rasmussen KK, Wehner PS o.a. Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients. Leukemia. 2015;29(2):297-303. https://doi.org/10.1038/leu.2014.205

Author

Wesołowska-Andersen, A ; Borst, L ; Dalgaard, M D ; Yadav, R ; Rasmussen, K K ; Wehner, P S ; Rasmussen, Morten ; Ørntoft, T F ; Nordentoft, I ; Koehler, R ; Bartram, C R ; Schrappe, M ; Sicheritz-Ponten, T ; Gautier, L ; Marquart, H ; Madsen, H O ; Brunak, S ; Stanulla, M ; Gupta, R ; Schmiegelow, K. / Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients. I: Leukemia. 2015 ; Bind 29, Nr. 2. s. 297-303.

Bibtex

@article{dfb9e87d16bf430d846b39f600df8185,
title = "Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients",
abstract = "Childhood acute lymphoblastic leukemia survival approaches 90%. New strategies are needed to identify the 10-15% who evade cure. We applied targeted, sequencing-based genotyping of 25 000 to 34 000 preselected potentially clinically relevant single-nucleotide polymorphisms (SNPs) to identify host genome profiles associated with relapse risk in 352 patients from the Nordic ALL92/2000 protocols and 426 patients from the German Berlin-Frankfurt-Munster (BFM) ALL2000 protocol. Patients were enrolled between 1992 and 2008 (median follow-up: 7.6 years). Eleven cross-validated SNPs were significantly associated with risk of relapse across protocols. SNP and biologic pathway level analyses associated relapse risk with leukemia aggressiveness, glucocorticosteroid pharmacology/response and drug transport/metabolism pathways. Classification and regression tree analysis identified three distinct risk groups defined by end of induction residual leukemia, white blood cell count and variants in myeloperoxidase (MPO), estrogen receptor 1 (ESR1), lamin B1 (LMNB1) and matrix metalloproteinase-7 (MMP7) genes, ATP-binding cassette transporters and glucocorticosteroid transcription regulation pathways. Relapse rates ranged from 4% (95% confidence interval (CI): 1.6-6.3%) for the best group (72% of patients) to 76% (95% CI: 41-90%) for the worst group (5% of patients, P<0.001). Validation of these findings and similar approaches to identify SNPs associated with toxicities may allow future individualized relapse and toxicity risk-based treatments adaptation.",
keywords = "Adolescent, Child, Child, Preschool, Denmark, Female, Genome, Human, Genomics, Genotype, Germany, Humans, Infant, Male, Neoplasm Recurrence, Local, Neoplasm, Residual, Polymorphism, Genetic, Polymorphism, Single Nucleotide, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Risk Factors, Treatment Outcome",
author = "A Weso{\l}owska-Andersen and L Borst and Dalgaard, {M D} and R Yadav and Rasmussen, {K K} and Wehner, {P S} and Morten Rasmussen and {\O}rntoft, {T F} and I Nordentoft and R Koehler and Bartram, {C R} and M Schrappe and T Sicheritz-Ponten and L Gautier and H Marquart and Madsen, {H O} and S Brunak and M Stanulla and R Gupta and K. Schmiegelow",
year = "2015",
doi = "10.1038/leu.2014.205",
language = "English",
volume = "29",
pages = "297--303",
journal = "Leukemia",
issn = "0887-6924",
publisher = "nature publishing group",
number = "2",

}

RIS

TY - JOUR

T1 - Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients

AU - Wesołowska-Andersen, A

AU - Borst, L

AU - Dalgaard, M D

AU - Yadav, R

AU - Rasmussen, K K

AU - Wehner, P S

AU - Rasmussen, Morten

AU - Ørntoft, T F

AU - Nordentoft, I

AU - Koehler, R

AU - Bartram, C R

AU - Schrappe, M

AU - Sicheritz-Ponten, T

AU - Gautier, L

AU - Marquart, H

AU - Madsen, H O

AU - Brunak, S

AU - Stanulla, M

AU - Gupta, R

AU - Schmiegelow, K.

PY - 2015

Y1 - 2015

N2 - Childhood acute lymphoblastic leukemia survival approaches 90%. New strategies are needed to identify the 10-15% who evade cure. We applied targeted, sequencing-based genotyping of 25 000 to 34 000 preselected potentially clinically relevant single-nucleotide polymorphisms (SNPs) to identify host genome profiles associated with relapse risk in 352 patients from the Nordic ALL92/2000 protocols and 426 patients from the German Berlin-Frankfurt-Munster (BFM) ALL2000 protocol. Patients were enrolled between 1992 and 2008 (median follow-up: 7.6 years). Eleven cross-validated SNPs were significantly associated with risk of relapse across protocols. SNP and biologic pathway level analyses associated relapse risk with leukemia aggressiveness, glucocorticosteroid pharmacology/response and drug transport/metabolism pathways. Classification and regression tree analysis identified three distinct risk groups defined by end of induction residual leukemia, white blood cell count and variants in myeloperoxidase (MPO), estrogen receptor 1 (ESR1), lamin B1 (LMNB1) and matrix metalloproteinase-7 (MMP7) genes, ATP-binding cassette transporters and glucocorticosteroid transcription regulation pathways. Relapse rates ranged from 4% (95% confidence interval (CI): 1.6-6.3%) for the best group (72% of patients) to 76% (95% CI: 41-90%) for the worst group (5% of patients, P<0.001). Validation of these findings and similar approaches to identify SNPs associated with toxicities may allow future individualized relapse and toxicity risk-based treatments adaptation.

AB - Childhood acute lymphoblastic leukemia survival approaches 90%. New strategies are needed to identify the 10-15% who evade cure. We applied targeted, sequencing-based genotyping of 25 000 to 34 000 preselected potentially clinically relevant single-nucleotide polymorphisms (SNPs) to identify host genome profiles associated with relapse risk in 352 patients from the Nordic ALL92/2000 protocols and 426 patients from the German Berlin-Frankfurt-Munster (BFM) ALL2000 protocol. Patients were enrolled between 1992 and 2008 (median follow-up: 7.6 years). Eleven cross-validated SNPs were significantly associated with risk of relapse across protocols. SNP and biologic pathway level analyses associated relapse risk with leukemia aggressiveness, glucocorticosteroid pharmacology/response and drug transport/metabolism pathways. Classification and regression tree analysis identified three distinct risk groups defined by end of induction residual leukemia, white blood cell count and variants in myeloperoxidase (MPO), estrogen receptor 1 (ESR1), lamin B1 (LMNB1) and matrix metalloproteinase-7 (MMP7) genes, ATP-binding cassette transporters and glucocorticosteroid transcription regulation pathways. Relapse rates ranged from 4% (95% confidence interval (CI): 1.6-6.3%) for the best group (72% of patients) to 76% (95% CI: 41-90%) for the worst group (5% of patients, P<0.001). Validation of these findings and similar approaches to identify SNPs associated with toxicities may allow future individualized relapse and toxicity risk-based treatments adaptation.

KW - Adolescent

KW - Child

KW - Child, Preschool

KW - Denmark

KW - Female

KW - Genome, Human

KW - Genomics

KW - Genotype

KW - Germany

KW - Humans

KW - Infant

KW - Male

KW - Neoplasm Recurrence, Local

KW - Neoplasm, Residual

KW - Polymorphism, Genetic

KW - Polymorphism, Single Nucleotide

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Risk Factors

KW - Treatment Outcome

U2 - 10.1038/leu.2014.205

DO - 10.1038/leu.2014.205

M3 - Journal article

C2 - 24990611

VL - 29

SP - 297

EP - 303

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -

ID: 152246116